NEA-backed Rhythm Holding Raises $11 Million
Rhythm Holding Company LLC has secured $11 million from sale of shares to three investors, according to an SEC filing.
The Boston-based company, founded earlier this year, develops peptide therapeutics for diseases like obesity and diabetes-related complications. It is led by CEO Dr. Keith M. Gottesdiener, who joined Rhythm after 16 years at Merck Research Laboratories.
According to the company website, Rhythm has raised a total of $73 million in two rounds of equity financing from investors including MPM Capital, New Enterprise Associates, Third Rock Ventures, Ipsen and Pfizer Venture Investments.